Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.77 0.06 −0.77%
Market cap
$451.7M
P/E
20.4×
Fwd P/E
0.0×
Dividend yield
5.41%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

19.28 20.17 23.83 19.32
P/S ratio
2.34 2.26 2.71 2.21
P/FCF ratio
22.27 26.00 30.09 16.15
P/Operating CF
39.21 53.79 (1,691.74) 23.52
P/B ratio
1.54 1.51 1.90 1.58
Price to Tangible BV
1.74 1.70 2.15 1.78
EV/Sales
2.05 1.95 2.42 1.94
EV/EBITDA
8.32 8.56 10.86 8.61
EV/Operating CF
12.63 13.82 17.13 10.39
EV/FCF
19.51 22.50 26.93 14.12
Quick Ratio
2.24 2.28 1.90 2.29
Current Ratio
4.03 4.07 3.33 4.06
Net Debt/EBITDA
(5.31) (8.92) (5.79) (4.78)
Debt/Assets
2.81% 2.62% 2.78% 1.57%
Debt/Equity
0.04 0.04 0.04 0.02
Asset Turnover
0.48 0.48 0.48 0.51
Operating CF/Net income
1.97 2.12 (0.07) 1.95
Capex/Depreciation
(0.95) (0.73) (0.25) (0.54)
Interest Coverage
35.37 13.71 36.98 25.63
Research and Development Expense of Revenue
5.61% 6.48% 4.82% 4.01%
Selling, General and Administrative Expense of Revenue
19.83% 23.55% 22.06% 19.59%
Intangible Assets out of Total Assets
0.08 0.08 0.08 0.08
Share Based Compensation of Revenue
0.25% 1.03% 1.77% 1.31%
Graham Net Nets
0.20 0.21 0.15 0.20
Graham Number
6.04 6.06 5.88 6.31
Earnings Yield
5.19% 4.96% 4.20% 5.18%
Free Cash Flow Yield
4.49% 3.85% 3.32% 6.19%
Revenue per Share
0.80 0.78 0.77 0.95
Operating CF per Share
0.18 0.13 0.00 0.31
Capex per Share
(0.06) (0.05) (0.02) (0.04)
Free Cash Flow per Share
0.12 0.08 (0.02) 0.28
Cash per Share
1.22 1.31 1.24 1.21
Shareholders Equity per Share
4.51 4.67 4.39 4.66
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.51 4.67 4.39 4.66
Free Cash Flow
6.83 4.79 (1.26) 15.96
Working Capital
144.90 145.68 139.46 150.42
Capital Expenditures
(3.59) (2.77) (0.97) (2.11)
Net Current Asset Value
80.76 83.44 75.60 85.97
EV/EBIT
12.89 13.42 17.35 13.35
Capex to Sales
0.08 0.06 0.02 0.04
Price to Operating Income
14.71 15.51 19.39 15.27
Other line items
Average Receivables
28.09 29.88 37.27 38.89
Average Payables
28.60 36.38 45.52 37.28
Average Inventory
78.49 81.88 81.90 84.48
Average Assets
364.21 375.48 379.06 375.67
Average Common Equity
260.25 264.27 255.67 264.76

Fold the line items

Columns are period end dates